Gain Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting companyEmerging growth company
State of Incorporation
DE
Business Address
4800 HAMPDEN LANE, BETHESDA, MD, 20814
Mailing Address
4800 HAMPDEN LANE, BETHESDA, MD, 20814
Phone
(301) 500-1556
Fiscal Year End
1231
EIN
851726310
Financial Overview
FY2025
-$20.16M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 26, 2026 | View on SEC |
| 10-K Annual financial report | March 26, 2026 | View on SEC |
| 4 Insider stock transaction report | March 26, 2026 | View on SEC |
| 8-K Current report of material events | March 18, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| 8-K Current report of material events | November 28, 2025 | View on SEC |
| 424B5 Prospectus supplement | November 28, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
Annual Reports
10-K
March 26, 2026
- Advancement of lead drug candidate GT-02287 into Phase 1b patient trials for Parkinson's disease.
- Proven ability of GT-02287 to successfully cross the blood-brain barrier, a major technical hurdle.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.